XLO News and Press, Xilio Therapeutics Inc. From 07/11/22

Gainers: Pliant Therapeutics ( PLRX ) +114% . Kaspien Holdings ( KSPN ) +99% . Iterum Therapeutics ( ITRM ) +83% . La Jolla Pharmaceutical Company ( LJPC ) +81% . Digital World Acquisition ( DWACW ) +51% . Volcon ( VLCN )...

Gainers: Rubicon Technology ( RBCN ) +68% . Faraday Future Intelligent Electric ( FFIE ) +65% . Ra Medical Systems ( RMED ) +61% . Xilio Therapeutics ( XLO ) +35% . Maris-Tech ( MTEK ) +35% . Lexicon Pharmaceuticals ( LXRX ...

Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies ...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medica...

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to further the ...

Xilio Therapeutics press release (NASDAQ:XLO): Q1 GAAP EPS of -$0.78 beats by $0.21. Cash and cash equivalents were $177.0 million as of March 31, 2022, as compared to $198.1 million as of December 31, 2021. For further details see: Xilio Therapeutics GAAP EPS of -$0.78 beats by $0.21 ...

Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for XTX301, a tumor-selective IL-12, in second half of 2022 Strong financial p...

Gainers: Universal Display Corporation (OLED) +10%. United Airlines Holdings (UAL) +8%. Seres Therapeutics (MCRB) +7%. Tesla (TSLA) +7%. Sono Group  (SEV) +7%. Losers: Xilio Therapeutics (XLO) -14%. BELLUS Health  (BLU) -7%. Sleep Number Corporation (SNBR)&#...

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medi...